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To investigate the association of combined serum neurofilament light chain (sNfL) and retinal
optical coherence tomography (OCT) measurements with future disease activity in patients
with early multiple sclerosis (MS).
Methods
We analyzed sNfL by single molecule array technology and performedOCTmeasurements in a
prospective cohort of 78 patients with clinically isolated syndrome and early relapsing-remitting
MS with a median (interquartile range) follow-up of 23.9 (23.3–24.7) months. Patients were
grouped into those with abnormal or normal sNfL levels, defined as sNfL ≥/<80th percentile of
age-corrected reference values. Likewise, patients were grouped by a median split into those
with thin or thick ganglion cell and inner plexiform layer (GCIP), peripapillary retinal nerve
fiber layer, and inner nuclear layer in nonoptic neuritis eyes. Outcome parameters were vio-
lation of no evidence of disease activity (NEDA-3) criteria or its components.
Results
Patients with abnormal baseline sNfL had a higher risk of violating NEDA-3 (hazard ratio [HR]
2.28, 95% CI 1.27–4.09, p = 0.006) and developing a new brain lesion (HR 2.47, 95% CI
1.30–4.69, p = 0.006), but not for a new relapse (HR 2.21, 95% CI 0.97–5.03, p = 0.058).
Patients with both abnormal sNfL and thin GCIP had an even higher risk for NEDA-3 violation
(HR 3.61, 95% CI 1.77–7.36, p = 4.2e−4), new brain lesion (HR 3.19, 95% CI 1.51–6.76, p =
0.002), and new relapse (HR 5.38, 95% CI 1.61–17.98, p = 0.006) than patients with abnormal
sNfL alone.
Conclusions
In patients with early MS, the presence of both abnormal sNfL and thin GCIP is a stronger risk
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Universität zu Berlin, and Berlin Institute of Health, Germany; and Department of Neurology (A.U.B.), University of California, Irvine.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by MDC Repository
Multiple sclerosis (MS) usually manifests with a monophasic
demyelinating episode, referred to as clinically isolated syn-
drome (CIS).1,2 As the further clinical course of MS can be
highly variable,3 reliable biomarkers for future disease activity
in patients at early stage of the disease are valuable for in-
dividual counseling and guiding treatment decisions.
Optical coherence tomography (OCT) is a noninvasive
technique that can visualize axonal loss (peripapillary retinal
nerve fiber layer [pRNFL] thinning), neuronal damage
(ganglion cell and inner plexiform layer [GCIP] thinning),
and neuroinflammation (inner nuclear layer [INL] edema) in
the retina.4-7 Our previous work showed that in patients with
CIS, reduced GCIP thickness is associated with future disease
activity.8
Neurofilament light chain (NfL) protein is a promising bio-
marker for neuroaxonal damage.9,10 Serum NfL (sNfL) levels
in MS were found to increase in cases where MRI measure-
ments indicated new or enlarged brain lesions and decreased
brain volume and were associated with diffuse white matter
damage.9,11-14 In addition, higher sNfL levels in patients with
early MS were also associated with higher probability of dis-
ability worsening.15
Despite the fact that retinal layer thinning is a chronic process,
and sNfL reflects shorter-term disease activity,9,16 both pa-
rameters may each provide a value for subsequent disease
activity. However, the combined association of elevated sNfL
and abnormal OCTmeasurements with future disease activity
in patients with CIS/early MS has not been well-explored.
In this study, we aimed at investigating the potentially additive
value of sNfL and OCT measurements as markers for sub-
sequent disease activity in patients with CIS or early MS.
Methods
Study Design
All patients included in this study participate in an ongoing
prospective, observational cohort study (Berlin CIS cohort:
ClinicalTrials.gov identifier: NCT01371071) at the Neuro-
Cure Clinical Research Center, Charité–Universitaẗsmedizin
Berlin of patients with a CIS or early MS (up to 2 years since
disease onset) according to the McDonald 2017 criteria.2 The
baseline OCT measurements and sNfL samples in this study
were collected at the same visit. All patients underwent annual
follow-up visits for clinical examination, serum sample col-
lection, retinal OCT, and brain MRI scanning.
Inclusion criteria for this study were (1) the availability of
baseline serum samples obtained between 12 and 24 months
after the first disease manifestation and (2) a follow-up period
of at least 12 months after enrollment. Exclusion criteria were
(1) relapse events within 120 days before the study inclusion,
(2) optic neuritis (ON) in both eyes, or (3) contraindications
for OCT analysis, including a refractive error above ±6 di-
opters or retinopathy unrelated to MS.
The primary study outcome was violating the no evidence of
disease activity (NEDA-3) criteria, which are composed of the
absence of new relapses, no new gadolinium-enhancing
(Gd+) or T2-hyperintense lesions onMRI, and the absence of
confirmed Expanded Disability Status Scale (EDSS) wors-
ening.17 We also analyzed the 3 components of NEDA-3 as
separate outcome parameters. Confirmed EDSS worsening
was defined as an increase of at least 1.5, 1.0, or 0.5 and
consequently being sustained in the consecutive annual
follow-up visit in patients with a baseline EDSS score of 0, at
least 1.0 or above 5.5, respectively.18
Standard Protocol Approvals, Registrations,
and Patient Consents
This study followed the Declaration of Helsinki in its currently
applicable version and was approved by the institutional ethics
committee at the Charité–Universitaẗsmedizin Berlin (EA1/
182/10). All participants provided written informed consent
before their inclusion in the study.
sNfL Measurements
sNfL was measured at the Department of Neurology, Uni-
versity of Basel, Switzerland, in frozen serum samples shipped
on dry ice. Operators masked to clinical data performed the
analysis using a highly sensitive single molecule array (Simoa
Technology; QUANTERIX Corporation, Billerica, MA)
immunoassay.11,19
Optical Coherence Tomography
All OCT images were obtained under normal room light
conditions by experienced operators through spectral domain
OCT and Heidelberg Eye Explorer (HeyEx) version 1.9.10.0
Glossary
3D = 3-dimensional; ART = automatic real-time; CIS = clinically isolated syndrome; DMT = disease-modifying therapy;
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(Heidelberg Engineering, Heidelberg, Germany) with auto-
matic real-time (ART) function for image averaging and an
activated eye tracker. All individual scans were quality con-
trolled according to the OSCAR-IB criteria20,21 and reported
based on the APOSTEL recommendations.22 A peripapillary
circular scan within a 12° (;3.4 mm) diameter ring (1,536
A-scans; 9 ≤ ART ≤ 99) around the optic nerve head was used
to measure the pRNFL thickness. The pRNFL on ring scans
was segmented with HeyEx viewing module version 6.0.14.0.
Macular volume scans (25° × 30°, 61 vertical B-scans, 12 ≤
ART ≤ 18) were segmented with the SAMIRIX pipeline.23
The GCIP and INL thickness were calculated as a 6-mm
diameter cylinder around the fovea.24 Segmentation errors
were manually corrected if necessary.
MRI
All MRI data were acquired using two 3 T machines (Tim
Trio; Siemens, Erlangen, Germany). The scanning protocol
included a 3-dimensional (3D) T1-weighted magnetization
prepared rapid acquisition gradient echo (MPRAGE) se-
quence (repetition time [TR] = 1,900 milliseconds, echo time
[TE] = 2.55 milliseconds, inversion time [TI] = 900 milli-
seconds) for precontrast and postcontrast administration and
3D T2-weighted (T2w) fluid-attenuated inversion recovery
(FLAIR) sequence (TR/TE/TI = 6,000/388/2,100 milli-
seconds; 1 × 1 × 1 mm3 resolution).
For brain lesion segmentation, precontrast and postcontrast
MPRAGE images were coregistered to MNI-152 standard
space for all patients using FMRIB’s Linear Image Registra-
tion Tool from FMRIB Software Library with linear-rigid
registration.25,26 Subsequently, FLAIR images were coregis-
tered with precontrast MPRAGE images. Brain T2-
hyperintense lesions were manually marked and segmented
using both FLAIR andMPRAGE scans to create binary masks
by 2 expert raters under the supervision of a board-certified
radiologist using ITK-SNAP (itksnap.org).27 Gd+ lesions
were segmented by the same raters and ITK-SNAP using
postcontrast MPRAGE scans only.
Statistical Analysis
Statistical analysis was performed in R version 4.0.2 with
packages lme4, lmerTest, MuMIn, ggplot2, ggpubr, survival,
and survminer.28 Continuous variables are presented as either
mean with SD or median with interquartile range (IQR).
Only OCT measurements of eyes with no history of ON at
baseline were included. GCIP was considered the primary
OCT variable because it has shown highest associations with
future disease activity in an earlier study,8 whereas pRNFL
and INL were analyzed as exploratory variables.
Age-specific sNfL percentile values were calculated from a
generalized additive models for location scale and shape
model based on a large cohort of 259 healthy controls pro-
vided by the Department of Neurology, University of Basel,
Switzerland.9 Under the concern of potential ceiling effect
while using percentiles, age-specific sNfL Z-scores were also
derived from the same model.
The baseline associations of sNfL and OCT measurements
including pRNFL, GCIP, and INL thickness were analyzed
using linear mixed effect model (LMM) (fixed effect: sNfL
value; random effects: inter-eye within-patient correlations).
No imputation was carried out in the analysis.
To investigate the risk of violating the NEDA-3 criteria or its
components with sNfL or/andOCT parameters as risk factors,
Kaplan-Meier analyses and Cox regression models were
implemented. In case of measurements for 2 non-ON eyes
were available, the mean of both eyes was used. After per-
forming sensitivity analysis (eTable 1, links.lww.com/NXI/
A523, and eTable 2, links.lww.com/NXI/A524), we defined
sNfL values higher than the 80th percentile as abnormal sNfL
and used median as dividers for each OCT parameter. Thinner
pRNFL and GCIP and thicker INL were considered as patho-
logic, respectively. To assess the individual risk associated with a
combination of sNfL and OCT groups, we combined the sNfL
andOCTparameters together as 1 variable with 4 categories: (1)
normal sNfL + thick GCIP/thick pRNFL/thin INL, (2) normal
sNfL + thinGCIP/thin pRNFL/thick INL, (3) abnormal sNfL +
thick GCIP/thick pRNFL/thin INL, and (4) abnormal sNfL +
thin GCIP/thin pRNFL/thick INL. In addition, we computed
multivariable Cox regression models including—besides sNfL
and GCIP thickness—age, sex, T2w lesion counts, and disease-
modifying therapy (DMT), which are previously established
factors associated with future disease activity in patients with
CIS/earlyMS.29 Analysis was censored after 760 days because of
low numbers at risk after this period. Furthermore, we evaluated
the interaction term between sNfL and GCIP thickness in the
Cox regression models and the synergistic effects between the 2
factors by calculating the attributable proportion that was be-
cause of their interaction as a measure of excess risk.30
Data Availability




Of 131 patients with CIS or early MS screened, 78 patients
met all the inclusion criteria. Eight patients had baseline sNfL
value acquired more than 24 months after the initial attack; 29
patients did not have follow-up of more than 365 days; 10
patients had a relapse within 120 days before the baseline
sNfL collection; 2 patients had ON in both eyes; 4 patients
had OCTmeasurements with insufficient quality in both eyes
(eFigure 1, links.lww.com/NXI/A518).20,21
Among the 78 patients included, 2 pRNFL measurements
from 2 patients and 5 GCIP and INL measurements from 5
other patients with insufficient OCT quality in 1 eye were
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omitted from the respective analyses. Sixty-two (79%) patients
fulfilled the 2017McDonaldMS diagnostic criteria for relapsing-
remitting MS (RRMS)2; the remaining 16 (21%) patients were
considered CIS. Eighteen (23%) patients with RRMS had clin-
ically definite MS, defined by a second clinical episode. De-
mographic and clinical characteristics of the study cohort are
summarized in Table 1, and comorbidities are described in
supplemental data (eTable 3, links.lww.com/NXI/A525).
Baseline Associations
LMM revealed an association between baseline age-specific
sNfL Z-score with GCIP (B [SE] = −0.921 [0.448] μm, p =
0.043), indicating that patients with 1 SD higher in sNfL Z-score
had a lower GCIP thickness by 0.921 μm. No association be-
tween baseline sNfL Z-score with pRNFL (B [SE] = −1.495
[0.795] μm, p= 0.064) or INL (B [SE] = −0.156 [0.168] μm, p=
0.356) was found (eFigure 2, links.lww.com/NXI/A519).
Association of sNfL and Retinal Thickness
Measurements With Future Disease Activity
Of the 78 patients included in this study, 46 (59%) patients
violated NEDA-3, 23 (29%) patients experienced a clinical
relapse, 38 (49%) patients developed new T2w or Gd+ brain
lesions on MRI, and 9 (12%) patients had confirmed EDSS
worsening during a median follow-up of 23.9 months. We first
investigated baseline abnormal sNfL (≥80th reference per-
centile), thinner pRNFL (≤100 μm; median divider), thinner
GCIP (≤70.4 μm; median divider), and thicker INL
(≥36.4 μm; median divider) separately regarding an associa-
tion with the risk for future violation of the NEDA-3 criteria.
Patients with baseline abnormal sNfL showed a higher risk of
the NEDA-3 violation (hazard ratio [HR] 2.28, 95% CI
1.27–4.09, p = 0.006; Figure 1A), whereas thinner GCIP
(Figure 1D), thinner pRNFL (eFigure 3A, links.lww.com/
NXI/A520), or thicker INL (eFigure 3D) showed no signif-
icant association with future NEDA-3 violation. When ana-
lyzing the association of sNfL with single components of
NEDA-3, patients with abnormal sNfL had an increased risk
of developing new lesions (HR 2.47, 95% CI 1.30–4.69, p =
0.006; Figure 1C), but not for a new relapse (HR 2.21, 95%CI
0.97–5.03, p = 0.058; Figure 1B). Thinner GCIP was asso-
ciated with a higher risk of a new relapse (HR 2.88, 95% CI
1.18–7.01, p = 0.021; Figure 1E), but not for new lesions.
Neither abnormal sNfL nor OCT parameters showed an as-
sociation with future confirmed EDSS worsening (results not
shown). These results were also confirmed when taking OCT
measurements as continuous variables instead of di-
chotomizing into categorical variables (eTable 4, links.lww.
com/NXI/A526).
In the multivariable analysis, abnormal sNfL was associated
with the NEDA-3 violation (HR 2.11, 95% CI 1.16–3.86, p =
0.015) and a new lesion (HR 2.04, 95% CI 1.06–3.94, p =
0.033), whereas higher T2w lesion counts were associated with
future lesion development (HR 1.01, 95% CI 1.00–1.03, p =
0.043). Patients with thinner GCIP had a higher, yet non-
significant risk of new clinical relapse compared with patients
with thicker GCIP. The risk of violating the NEDA-3 criteria
was not affected by age, sex, or receiving DMT at the time of
study enrollment (Table 2). Higher T2w lesion volume was
also associated with subsequent NEDA-3 violation and lesion
development (eTable 5, links.lww.com/NXI/A527).
To analyze whether sNfL and OCT parameters combined
show stronger associations with future MS disease activity
than each parameter alone, we combined sNfL and different
OCT parameters as an univariable risk factor for further
analysis. For the NEDA-3 criteria violation, patients with (1)
abnormal sNfL + thin GCIP (HR 3.61, 95% CI 1.77–7.36, p =
4.2e−4; Figure 2A), (2) abnormal sNfL + thin pRNFL (HR
2.63, 95% CI 1.21–5.70, p = 0.015; eFigure 4A, links.lww.
com/NXI/A521), or (3) abnormal sNfL + thick INL (HR
3.05, 95% CI 1.32–7.05, p = 0.009; eFigure 4D), all have
increased risks in comparison with patients without abnormal
sNfL or thin GCIP/thin pRNFL/thick INL as risk factors.
Higher hazard ratios were observed when the sNfL and OCT
measurements were combined than abnormal sNfL or thin
GCIP/thin pRNFL/thick INL alone as a single risk factor, as
in the analysis above. Regarding the occurrence of new re-
lapses, the Cox regression analysis revealed a higher risk as-
sociated with (1) abnormal sNfL + thin GCIP (HR 5.38, 95%
CI 1.61–17.98, p = 0.006; Figure 2B), (2) abnormal sNfL +
thin pRNFL (HR 4.77, 95%CI 1.39–16.38, p = 0.013; eFigure
4B), or (3) abnormal sNfL + thick INL (HR 3.26, 95% CI
1.09–9.76, p = 0.034; eFigure 4E) as a combined univariable
risk factor. For new lesion development, an increased HR was
achieved when combining abnormal baseline sNfL value with
reduced GCIP thickness (HR 3.19, 95% CI 1.51–6.76, p =
0.002; Figure 2C). As for confirmed worsening of the EDSS
Table 1 Baseline Cohort Characteristics
Patients (N = 78)
Sex, F (%)/M (%) 50 (64.1)/28 (35.9)
Age, y, mean (SD) 33.7 (7.4)
sNfL level, pg/mL, median (IQR) 19.7 (15.2–28.8)
Time since disease onset, mo, median (IQR) 12.1 (11.8–12.7)
Follow-up duration, mo, median (IQR) 23.9 (23.3–24.7)
GCIP thickness, μm, mean (SD) 69.4 (7.1)
pRNFL thickness, μm, mean (SD) 98.7 (12.9)
INL thickness, μm, mean (SD) 36.8 (2.3)
Total T2w lesion count, N, median (IQR) 11 (5–28)
Total T2w lesion volume, mL, median (IQR) 1.1 (0.4–2.8)
EDSS score, median (IQR) 1.5 (1.0–2.0)
Abbreviations: EDSS = expanded disability status scale; GCIP = ganglion cell
and inner plexiform layer; INL = inner nuclear layer; IQR = interquartile
range; pRNFL = peripapillary retinal nerve fiber layer; sNfL = serum neuro-
filament light chain; T2w = T2-weighted.
4 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 5 | September 2021 Neurology.org/NN
Figure 1 Kaplan-Meier Plots for Meeting NEDA-3 Criteria or Its Components
Patients violating NEDA-3 criteria with (A) abnormal sNfL or (D) thin GCIP as risk factors, patients experiencing new relapse with (B) abnormal sNfL or (E) thin
GCIP as risk factors, and patients having new lesion development with (C) abnormal sNfL or (F) thin GCIP as risk factors. Shady regions describe the 95% CI of
the curve. GCIP = ganglion cell and inner plexiform layer; HR = hazard ratio; NEDA-3 = no evidence of disease activity-3 criteria; sNfL = serum neurofilament
light chain.
Table 2 Multivariable Analysis With Cox Proportional Hazard Models of Factors Associated With NEDA-3 Violation,
Relapse, and Lesion Development
NEDA-3 violation Relapse New lesion
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
sNfL ≥80th percentile 2.11 (1.16–3.86) 0.015a 1.98 (0.85–4.64) 0.114 2.04 (1.06–3.94) 0.033a
GCIP ≤70.4 μm 1.42 (0.78–2.60) 0.254 2.42 (0.97–6.03) 0.057 1.14 (0.58–2.26) 0.707
Age 1.00 (0.96–1.04) 0.864 0.99 (0.94–1.05) 0.746 1.00 (0.96–1.04) 0.815
Sex, male 1.39 (0.75–2.61) 0.299 1.51 (0.63–3.61) 0.355 0.89 (0.44–1.80) 0.745
T2w lesion count 1.01 (1.00–1.02) 0.081 1.01 (0.99–1.02) 0.531 1.01 (1.00–1.03) 0.043a
DMT at baseline 1.53 (0.82–2.84) 0.180 1.71 (0.68–4.26) 0.252 1.20 (0.61–2.36) 0.601
Abbreviations: DMT = disease-modifying therapy; GCIP = ganglion cell and inner plexiform layer; HR = hazard ratio; NEDA-3 = no evidence of disease activity-3
criteria; sNfL = serum neurofilament light chain; T2w = T2-weighted.
a Significant.
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score, a higher association cannot be achieved in combination
of sNfL with any of the 3 OCT parameters (results not
shown). A summary of the HRs for future disease activity
outcomes associated with abnormal sNfL and thinner GCIP
alone and their combination is presented in Figure 3.
The interaction between abnormal sNfL and thin GCIP is
summarized in the supplemental data (eTable 6, links.lww.
com/NXI/A528). We found an interaction effect between
abnormal sNfL and thin GCIP for future NEDA-3 violation
and new lesion development, but not for relapses. The
attributable proportion showed that the interaction of ab-
normal sNfL and thin GCIP added 75% to the subsequent
NEDA-3 violation risk and 85% to the new brain lesion risk
determined with the sum of the individual risks (eTable 6).
Discussion
We investigated the relation between baseline sNfL levels and
OCT and their individual and combined association with
future disease activity in a well-characterized cohort of pa-
tients with CIS or early MS. We found (1) a weak cross-
Figure 2Kaplan-Meier Plots ofMeetingNEDA-3 Criteria or Its ComponentsWith Abnormal sNfL andOCTMeasurements as
Combined Risk Factor
Cumulative risk of patientswith abnormal sNfL value and thin GCIP (black), abnormal sNfL value and thick GCIP (red), normal sNfL value and thin GCIP (green),
and normal sNfL value and thick GCIP (blue) for (A) NEDA-3 violation; (B) relapse; and (C) a new lesion. GCIP = ganglion cell and inner plexiform layer; HR =
hazard ratio; NEDA-3 = no evidence of disease activity-3 criteria; OCT = optical coherence tomography; sNfL = serum neurofilament light chain.
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sectional association of increased sNfL levels with thinner
GCIP but no association of sNfL with pRNFL or INL; (2) an
association of increased sNfL with future NEDA-3 violation,
mainly driven by the development of new lesions; (3) an
association of thinner GCIP with future relapses; and (4)
combinations of increased sNfL levels with thinner GCIP or
pRNFL or thicker INL is associated with a higher risk of
future disease activity than each parameter alone.
Two studies had previously investigated the relationship be-
tween sNfL and OCT values.31,32 These studies found contra-
dictory results regarding cross-sectional associations of sNfL
levels with retinal layer thickness measurements: The first study-
reported results of 80 patients with RRMS from a 3-year study
showed that an increase of sNfL level is associated with the
annual reduction of pRNFL.31 However, no cross-sectional as-
sociation of sNfL and pRNFL was identified. On the contrary,
the second study reported cross-sectional evidence that sNfL
concentration was significantly associated with both pRNFL and
GCIP from 110 patients withMS.32 Our baseline results showed
that the sNfL level is associated with GCIP but missed signifi-
cance for an association with pRNFL. Both studies have only
limited comparability with each other and to our study because
they analyzed patients with RRMS with a mean disease duration
of 4.6 years (SD 5.0)31 and a mixed RRMS and progressive MS
cohort with a median disease duration of 16.5 years (IQR
8.7–23.0),32 respectively, whereas our study included patients
with CIS and early MS with a median disease duration of 12.1
months (IQR 11.8–12.7). The association between increased
sNfL levels and neuroaxonal retinal damage might be more
pronounced in later and more progressive stages of the disease
because it was the case in the cohort of the second study.32
However, this potentially may not result from a causal associa-
tion but from a general and less focal chronic neurodegeneration.
In our study, abnormal sNfL levels were associated with an
increased risk of subsequent violation of the NEDA-3 criteria.
Regarding the components of the NEDA-3 criteria, abnormal
sNfL was especially related to a 2.5-fold increased risk of new
brain lesions development on MRI. As for the other 2 com-
ponents in the NEDA-3 criteria contravention, we did not
observe an association of abnormal sNfL with future relapses
or confirmed EDSS worsening. Only 9 patients in our cohort
had confirmed EDSS increase within the observation period,
limiting the power of the latter analyses.
To determine whether the effects of sNfL were independently
associated with future disease activity, several risk factors for
MS disease activity were included for the multivariable analysis.
Patients with more brain MRI lesions were identified to be a
high-impact prognostic factor for future disease activity in large
prospective cohorts previously.29,33 Nevertheless, our study
demonstrated that patients with more T2w lesions on brain
MRI had a higher but nonsignificant HR for violating the
NEDA-3 criteria. The resulting difference could be explained
by the fact that our study only had a relatively small sample size
and shorter follow-up duration compared with the previous
studies. Furthermore, our cohort comprised patients with a
higher lesion burden than in other studies, in which a large
portion of patients did not show any lesion at all.
Our group has shown earlier that thinner GCIP and pRNFL
are associated with future disease activity in CIS and early MS,
in a cohort partly overlapping with this study.8 Interestingly,
the association of thinner GCIP and pRNFL with future
NEDA-3 violation was almost exclusively driven by an asso-
ciation with new lesions in the previous study; although in this
study, it is mainly driven by an association with future re-
lapses. This can be explained by (1) different patients—only
31 patients who overlap between this and the previous study,
(2) different timepoints—the earlier study established the
baseline visit in the first year after onset, whereas the baseline
for this study is at the end of the first or second year after
disease onset, (3) diagnostic criteria—the earlier study in-
cluded patients with CIS in line with the 2010 McDonald
criteria; this study included patients with CIS and RRMS in
Figure 3 Abnormal sNfL Alone or Combined With Thin GCIP for Risk Stratification of Subsequent Disease Activity
GCIP = ganglion cell and inner plexiform layer; HR = hazard
ratio; NEDA-3 = no evidence of disease activity-3 criteria; sNfL
= serum neurofilament light chain.
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line with the 2017 McDonald criteria, and (4) different
protocols—this study has only annual MRI follow-up visits,
whereas patients received more frequent follow-ups in the
first year after onset, which was analyzed in the earlier study.
Despite these differences, we would have expected a stronger
association of thinner GCIP with future new lesions. An in-
vestigation of those associations in larger and independent
cohorts would be helpful to unravel these inconsistencies.
The most important finding of our study is that thinning of
GCIP and pRNFL can both provide combined benefits to
abnormal sNfL regarding their association with subsequent
NEDA-3 violation, as demonstrated by higher HRs. In addi-
tion, abnormal sNfL value with thinner pRNFL or GCIP shows a
higher association with future relapses, and abnormal sNfL value
with thinner GCIP shows a higher HR for a new lesion, in
comparison to sNfL alone, respectively. The combined benefits of
sNfL with either GCIP or pRNFL thickness may be explained by
the nature of the biomarkers. The concentration of sNfL in
samples collected within 3–4 months after relapse was signifi-
cantly higher compared with the samples collected after this time
windowor during remission phase.9,16 In contrast with sNfL, both
GCIP and pRNFL thickness on OCT show continuous thinning
over time, reflecting a chronic neuroaxonal injury.6 Patients with
MSwho have both abnormal acute and chronic biomarkers could
indicate that the damage ismore profound, leading to a higher rate
of NEDA-3 violation. Together, our data suggest a synergistic
effect of GCIP/pRNFL and sNfL measurements and exemplifies
the potential when combining biomarkers to increase disease
relevance. NfL by itself is unspecific forMS-related damage as it is,
e.g., increased in other neurodegenerative disorders34 and in as-
sociation with cardiovascular risk factors or traumatic brain in-
jury.35 The normal range of pRNFL andGCIP thickness is broad,
impeding an individual risk assessment in earlyMS.8 But together,
the combination of abnormal sNfL and thin GCIP/pRNFL may
have the specificity to identify a group of patients in which both
markers are related to MS-associated damage and thus outper-
forms the prognostic value of each marker alone.
INL thickening can mirror not only active retinal in-
flammation but the inflammatory status of MS disease activ-
ity.36 Longitudinal reduction in INL volume was found to be
correlated with meeting the NEDA-3 criteria.37 Although, in
our study, thicker INL alone was not a risk factor for future
disease activity, we still demonstrate that thicker INL in-
creases the hazard ratio of abnormal sNfL as a risk factor for
NEDA-3 violation and new relapses. The thickening of INL in
MS could be caused by dynamic change of fluid homeostasis
in the retinal glymphatic system or dysfunction of the Müller
cell.36 However, the true mechanism of INL thickening in
patients with MS remains unclear. Therefore, although INL
thickening and elevated sNfL level both suggest active in-
flammation in patients with MS, no established evidence has
proven the causality between them.
The timing for retinal OCT examination and sNfL sample
collection should be taken into consideration in clinical
application. During acute episode, the pRNFL is often af-
fected by early inflammation or edema within 3 months,
whereas GCIP thickness seems to decrease.38-40 Afterward,
both pRNFL and GCIP continue to have progressive
thinning.39,40 Therefore, the quantification of retinal layer
thickness should be made no earlier than 3 months after the
attack. On the other hand, the concentration of sNfL will
transiently increase during relapse11 and is likely to return to a
steady state 4 months afterwards.9,16 Our study started with
12 months after first clinical event and excluded patients with
clinical relapses within 120 days before the inclusion, pre-
senting the utility of these 2 biomarkers under a disease stable
phase.
Strengths of our study include its prospective design, stan-
dardized acquisition of clinical and paraclinical data, and a
decent follow-up time. In addition, the dividers we chose for
sNfL and OCT measurements are similar to previous studies,
supporting the generalizability of our results.31,41 However,
because only few patients showed confirmed EDSS worsening
during the follow-up period, we could not adequately address
the influence of sNfL and OCT parameters on EDSS wors-
ening. The limited sample size may also mask significant ef-
fects of age, sex, or treatment in the multiple Cox regression
model. In addition, our study lacks the power to determine
the optimal cutoff value for either sNfL or OCT parameters
through receiver operator characteristic analyses, limiting the
generalizability of our results. Furthermore, there are several
factors that may cause within-subject sNfL variation.42-45 Al-
though none of the patients in our cohort have small infarcts
or neuropathy, we did not adjust the analysis for body mass
index, participation in physical contact sports, high systolic
blood pressure, and hemoglobin A1c level. Larger-scope
multicenter studies should consider tackling these limitations
to establish more concrete evidence on the relationship be-
tween sNfL and different OCTmeasurements throughout the
disease course.
In conclusion, our study demonstrates an additive, potentially
synergistic, effect of sNfL and retinal OCT, especially GCIP,
as risk factors for future disease activity in patients with CIS or
early MS. Our findings encourage the application of both
sNfL and retinal measurements for risk stratification in clinical
routine and trials.
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